Nicotine Biomarkers and Rate of Nicotine Metabolism Among Cigarette Smokers Taking Buprenorphine for Opioid Dependency

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2017 Jul 7

PMID 28683421

Citations 6

Authors

Noah R Gubner

Joseph Guydish

Gary L Humfleet

Neal L Benowitz

Sharon M Hall

Affiliations

Soon will be listed here.

Abstract

Background: Individual differences in the rate of nicotine metabolism contribute to differences in tobacco use, dependence, and efficacy of smoking cessation treatments and can be assessed using the nicotine metabolite ratio (NMR), a validated biomarker for CYP2A6 activity. Despite the high cigarette smoking rates observed in opioid users, no data have been reported on NMR among this population as they has been largely excluded from previous studies that have examined the relationship between tobacco use characteristics and rate of nicotine metabolism.

Methods: A linear regression model was used to examine the relationship between tobacco use characteristics and NMR among smokers taking buprenorphine for opioid dependency (N=141). The relationship between buprenorphine dose and NMR was also examined. All participants were enrolled in an intervention designed to promote cigarette-smoking cessation, though participants did not need to stop smoking to enroll.

Results And Conclusions: Rate of nicotine metabolism assessed using the NMR was positively associated with cigarettes smoked in the past 24h, but was not related to time to first cigarette or past year quit attempts. Dose of buprenorphine was not associated with NMR, suggesting no association with rate of nicotine metabolism. Our results suggest that NMR is related to tobacco use among persons enrolled in opioid treatment, as reported in general population smokers and may be a useful biomarker to include in future research assessing efficacy of tobacco cessation interventions in this population.

Citing Articles

Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.

Montgomery L, Winhusen T, Scodes J, Pavlicova M, Twitty D, Campbell A J Subst Abuse Treat. 2021; 130:108489.

PMID: 34118716 PMC: 8478713. DOI: 10.1016/j.jsat.2021.108489.

Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study.

Kranzler H, Washio Y, Zindel L, Lynch K, Hand D, Tyndale R Nicotine Tob Res. 2020; 22(10):1923-1927.

PMID: 32303761 PMC: 7542647. DOI: 10.1093/ntr/ntaa066.

The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions.

Siegel S, Lerman C, Flitter A, Schnoll R Cancer Prev Res (Phila). 2020; 13(3):261-272.

PMID: 32132120 PMC: 7080293. DOI: 10.1158/1940-6207.CAPR-19-0259.

Opiate and Tobacco Use and Exposure to Carcinogens and Toxicants in the Golestan Cohort Study.

Etemadi A, Poustchi H, Calafat A, Blount B, De Jesus V, Wang L Cancer Epidemiol Biomarkers Prev. 2020; 29(3):650-658.

PMID: 31915141 PMC: 7839071. DOI: 10.1158/1055-9965.EPI-19-1212.

Opioid Use and Rate of Nicotine Metabolism Among Pregnant Smokers.

Oncken C, Mead E, Dornelas E, Kuo C, Sankey H, Kranzler H Nicotine Tob Res. 2019; 22(6):1046-1050.

PMID: 31063550 PMC: 7249922. DOI: 10.1093/ntr/ntz073.

References

Bandiera F, Anteneh B, Le T, Delucchi K, Guydish J . Tobacco-related mortality among persons with mental health and substance abuse problems. PLoS One. 2015; 10(3):e0120581. PMC: 4373726. DOI: 10.1371/journal.pone.0120581. View

Kishioka S, Kiguchi N, Kobayashi Y, Saika F . Nicotine effects and the endogenous opioid system. J Pharmacol Sci. 2014; 125(2):117-24. DOI: 10.1254/jphs.14r03cp. View

Stark M, Campbell B . Cigarette smoking and methadone dose levels. Am J Drug Alcohol Abuse. 1993; 19(2):209-17. DOI: 10.3109/00952999309002681. View

Levi M, Dempsey D, Benowitz N, Sheiner L . Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. J Pharmacokinet Pharmacodyn. 2007; 34(1):23-34. DOI: 10.1007/s10928-006-9026-0. View

Zhang W, Ramamoorthy Y, Tyndale R, Sellers E . Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003; 31(6):768-72. DOI: 10.1124/dmd.31.6.768. View

Dempsey D, Tutka P, Jacob 3rd P, Allen F, Schoedel K, Tyndale R . Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004; 76(1):64-72. DOI: 10.1016/j.clpt.2004.02.011. View

Hall S, Humfleet G, Gasper J, Delucchi K, Hersh D, Guydish J . Cigarette Smoking Cessation Intervention for Buprenorphine Treatment Patients. Nicotine Tob Res. 2017; 20(5):628-635. PMC: 7207071. DOI: 10.1093/ntr/ntx113. View

Richter K, Gibson C, Ahluwalia J, Schmelzle K . Tobacco use and quit attempts among methadone maintenance clients. Am J Public Health. 2001; 91(2):296-9. PMC: 1446533. DOI: 10.2105/ajph.91.2.296. View

Baker T, Piper M, McCarthy D, Bolt D, Smith S, Kim S . Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res. 2008; 9 Suppl 4:S555-70. PMC: 2933747. DOI: 10.1080/14622200701673480. View

10.

Lerman C, Schnoll R, Hawk Jr L, Cinciripini P, George T, Wileyto E . Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015; 3(2):131-138. PMC: 4480925. DOI: 10.1016/S2213-2600(14)70294-2. View

11.

Nahvi S, Richter K, Li X, Modali L, Arnsten J . Cigarette smoking and interest in quitting in methadone maintenance patients. Addict Behav. 2006; 31(11):2127-34. DOI: 10.1016/j.addbeh.2006.01.006. View

12.

Hurt R, Offord K, Croghan I, Kottke T, Morse R, Melton 3rd L . Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA. 1996; 275(14):1097-103. DOI: 10.1001/jama.275.14.1097. View

13.

Schnoll R, George T, Hawk L, Cinciripini P, Wileyto P, Tyndale R . The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology (Berl). 2014; 231(12):2515-23. PMC: 4040302. DOI: 10.1007/s00213-013-3421-1. View

14.

Lerman C, Tyndale R, Patterson F, Wileyto E, Shields P, Pinto A . Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006; 79(6):600-8. DOI: 10.1016/j.clpt.2006.02.006. View

15.

Tyndale R, Sellers E . Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos. 2001; 29(4 Pt 2):548-52. View

16.

Richter K, Hamilton A, Hall S, Catley D, Cox L, Grobe J . Patterns of smoking and methadone dose in drug treatment patients. Exp Clin Psychopharmacol. 2007; 15(2):144-53. DOI: 10.1037/1064-1297.15.2.144. View

17.

Schmitz J, Grabowski J, Rhoades H . The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend. 1994; 34(3):237-42. DOI: 10.1016/0376-8716(94)90162-7. View

18.

Benowitz N, Hukkanen J, Jacob 3rd P . Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009; (192):29-60. PMC: 2953858. DOI: 10.1007/978-3-540-69248-5_2. View

19.

Chait L, Griffiths R . Effects of methadone on human cigarette smoking and subjective ratings. J Pharmacol Exp Ther. 1984; 229(3):636-40. View

20.

Jarvis M, Giovino G, OConnor R, Kozlowski L, Bernert J . Variation in nicotine intake among U.S. cigarette smokers during the past 25 years: evidence from NHANES surveys. Nicotine Tob Res. 2014; 16(12):1620-8. DOI: 10.1093/ntr/ntu120. View